help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by DAHL, R.
Right arrow Articles by DELLA CIOPPA, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by DAHL, R.
Right arrow Articles by DELLA CIOPPA, G.

Am. J. Respir. Crit. Care Med., Volume 164, Number 5, September 2001, 778-784

Inhaled Formoterol Dry Powder Versus Ipratropium Bromide in Chronic Obstructive Pulmonary Disease

RONALD DAHL, LOUIS A. P. M. GREEFHORST, DARIUSZ NOWAK, VLADIMIR NONIKOV, AIDAN M. BYRNE, MOIRA H. THOMSON, DENISE TILL, and GIOVANNI DELLA CIOPPA, on behalf of the Formoterol in Chronic Obstructive Pulmonary Disease I (FICOPD I) Study Group

University Hospital Aarhus, Department of Respiratory Diseases, Aarhus, Denmark; Streekziekenhuis Midden Twente, Hengelo, The Netherlands; Department of Physiology, Lodz, Poland; Central Clinical Hospital, Moscow, Russia; and Novartis Horsham Research Centre, Horsham, United Kingdom

We compared the effectiveness of inhaled formoterol with that of ipratropium in the treatment of chronic obstructive pulmonary disease (COPD). After a 2-wk run-in period, 780 patients with COPD were randomized to receive for 12 wk formoterol dry powder 12 or 24 µg twice daily, ipratropium bromide 40 µg four times daily, or placebo in a multicenter, double-blind, parallel-group study. The primary efficacy variable was the area under the curve for forced expiratory volume in 1 s (FEV1) measured over 12 h after 12 wk of treatment. Secondary variables included diary symptoms and quality of life. Both doses of formoterol and ipratropium significantly increased the area under the curve for FEV1 in comparison with placebo (all p < 0.001). Both doses of formoterol were also significantly superior to ipratropium (all p < 0.025). Compared with placebo, both doses of formoterol significantly improved symptoms (all p =< 0.007) and quality of life (p < 0.01 for total scores) whereas ipratropium did not show significant effects (all p >=  0.3). All study treatments exhibited a similar safety profile. We conclude that formoterol is more effective than ipratropium bromide in the treatment of COPD, as the efficacy of ipratropium on airflow obstruction does not translate into a clinical benefit that patients can perceive.

Keywords: chronic obstructive pulmonary disease; inhaled cholinergic antagonist; inhaled long-acting beta 2-agonist; formoterol; FEV1; quality of life; randomized controlled study




This article has been cited by other articles:


Home page
 The Annals of PharmacotherapyHome page
A. M Chen, S. G Bollmeier, and P. M Finnegan
Long-Acting Bronchodilator Therapy for the Treatment of Chronic Obstructive Pulmonary Disease
Ann. Pharmacother., December 1, 2008; 42(12): 1832 - 1842.
[Abstract] [Full Text] [PDF]

Home page
 Therapeutic Advances in Respiratory DiseaseHome page
J. F. Donohue, N. A. Hanania, C. Fogarty, S. C. Campbell, M. Rinehart, and K. Denis-Mize
Long-term safety of nebulized formoterol: Results of a twelve-month open-label clinical trial
Therapeutic Advances in Respiratory Disease, August 1, 2008; 2(4): 199 - 208.
[Abstract] [PDF]

Home page
 ChestHome page
K. F. Rabe, W. Timmer, A. Sagkriotis, and K. Viel
Comparison of a Combination of Tiotropium Plus Formoterol to Salmeterol Plus Fluticasone in Moderate COPD
Chest, August 1, 2008; 134(2): 255 - 262.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
B. R. Celli
Update on the Management of COPD
Chest, June 1, 2008; 133(6): 1451 - 1462.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
P. T. Diaz, A. S. Bruns, M. E. Ezzie, N. Marchetti, and B. M. Thomashow
Optimizing Bronchodilator Therapy in Emphysema
Proceedings of the ATS, May 1, 2008; 5(4): 501 - 505.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
G. J. Rodrigo, L. J. Nannini, and R. Rodriguez-Roisin
Safety of Long-Acting {beta}-Agonists in Stable COPD: A Systematic Review
Chest, May 1, 2008; 133(5): 1079 - 1087.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
Y. Oba
Does Tiotropium Reduce Hospitalizations in Chronic Obstructive Pulmonary Disease?
Ann Intern Med, April 15, 2008; 148(8): 626 - 626.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
C. Brouillard, V. Pepin, J. Milot, Y. Lacasse, and F. Maltais
Endurance shuttle walking test: responsiveness to salmeterol in COPD
Eur. Respir. J., March 1, 2008; 31(3): 579 - 584.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
P. G. Camp and S. M. Goring
Gender and the Diagnosis, Management, and Surveillance of Chronic Obstructive Pulmonary Disease
Proceedings of the ATS, December 1, 2007; 4(8): 686 - 691.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
T. J. Wilt, D. Niewoehner, R. MacDonald, and R. L. Kane
Management of Stable Chronic Obstructive Pulmonary Disease: A Systematic Review for a Clinical Practice Guideline
Ann Intern Med, November 6, 2007; 147(9): 639 - 653.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
N. A. Hanania and J. F. Donohue
Pharmacologic Interventions in Chronic Obstructive Pulmonary Disease: Bronchodilators
Proceedings of the ATS, October 1, 2007; 4(7): 526 - 534.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
K. F. Rabe, S. Hurd, A. Anzueto, P. J. Barnes, S. A. Buist, P. Calverley, Y. Fukuchi, C. Jenkins, R. Rodriguez-Roisin, C. van Weel, et al.
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: GOLD Executive Summary
Am. J. Respir. Crit. Care Med., September 15, 2007; 176(6): 532 - 555.
[Abstract] [Full Text] [PDF]

Home page
 ERRHome page
D. E. O'Donnell
Impacting patient-centred outcomes in COPD: breathlessness and exercise tolerance
Eur. Respir. Rev., December 1, 2006; 15(99): 37 - 41.
[Abstract] [Full Text] [PDF]

Home page
 ERRHome page
M. Decramer
Tiotropium as essential maintenance therapy in COPD
Eur. Respir. Rev., December 1, 2006; 15(99): 51 - 57.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
P. Tonnesen, K. Mikkelsen, and L. Bremann
Nurse-Conducted Smoking Cessation in Patients With COPD Using Nicotine Sublingual Tablets and Behavioral Support.
Chest, August 1, 2006; 130(2): 334 - 342.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
A. O. D'Souza, M. J. Smith, L. A. Miller, and J. Kavookjian
An Appraisal of Pharmacoeconomic Evidence of Maintenance Therapy for COPD
Chest, June 1, 2006; 129(6): 1693 - 1708.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
S Scott, P Walker, and P M A Calverley
COPD exacerbations {middle dot} 4: Prevention
Thorax, May 1, 2006; 61(5): 440 - 447.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
B. R. Celli
Chronic Obstructive Pulmonary Disease: From Unjustified Nihilism to Evidence-based Optimism.
Proceedings of the ATS, January 1, 2006; 3(1): 58 - 65.
[Abstract] [Full Text] [PDF]

Home page
 ERRHome page
W. Vincken
Bronchodilator treatment of stable COPD: long-acting anticholinergics
Eur. Respir. Rev., September 1, 2005; 14(94): 23 - 31.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
J. A. van Noord, J-L. Aumann, E. Janssens, J. J. Smeets, J. Verhaert, B. Disse, A. Mueller, and P. J. G. Cornelissen
Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD
Eur. Respir. J., August 1, 2005; 26(2): 214 - 222.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
J Vestbo, R Pauwels, J A Anderson, P Jones, P Calverley, and on behalf of the TRISTAN study group
Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease
Thorax, April 1, 2005; 60(4): 301 - 304.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
M Decramer, R Gosselink, P Bartsch, C-G Lofdahl, W Vincken, R Dekhuijzen, J Vestbo, R Pauwels, R Naeije, and T Troosters
Effect of treatments on the progression of COPD: report of a workshop held in Leuven, 11-12 March 2004
Thorax, April 1, 2005; 60(4): 343 - 349.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
M. Cazzola and R. Dahl
Inhaled Combination Therapy With Long-Acting {beta}2-Agonists and Corticosteroids in Stable COPD
Chest, July 1, 2004; 126(1): 220 - 237.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
E. R. Sutherland and R. M. Cherniack
Management of Chronic Obstructive Pulmonary Disease
N. Engl. J. Med., June 24, 2004; 350(26): 2689 - 2697.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
B.R. Celli, W. MacNee, A. Agusti, A. Anzueto, B. Berg, A.S. Buist, P.M.A. Calverley, N. Chavannes, T. Dillard, B. Fahy, et al.
Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper
Eur. Respir. J., June 1, 2004; 23(6): 932 - 946.
[Full Text] [PDF]

Home page
 ChestHome page
S. R. Salpeter, T. M. Ormiston, and E. E. Salpeter
Cardiovascular Effects of {beta}-Agonists in Patients With Asthma and COPD: A Meta-Analysis
Chest, June 1, 2004; 125(6): 2309 - 2321.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
S. Spencer, P.M.A. Calverley, P.S. Burge, and P.W. Jones
Impact of preventing exacerbations on deterioration of health status in COPD
Eur. Respir. J., May 1, 2004; 23(5): 698 - 702.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
M. Cazzola and M. G. Matera
Long-Acting Bronchodilators Are the First-Choice Option for the Treatment of Stable COPD
Chest, January 1, 2004; 125(1): 9 - 11.
[Full Text] [PDF]

Home page
 ChestHome page
D. P. Tashkin and C. B. Cooper
The Role of Long-Acting Bronchodilators in the Management of Stable COPD
Chest, January 1, 2004; 125(1): 249 - 259.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
P.M. Calverley, W. Boonsawat, Z. Cseke, N. Zhong, S. Peterson, and H. Olsson
Maintenance therapy with budesonide and formoterol in chronicobstructive pulmonary disease
Eur. Respir. J., December 1, 2003; 22(6): 912 - 919.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
B. R. Celli
A 62-Year-Old Woman With Chronic Obstructive Pulmonary Disease
JAMA, November 26, 2003; 290(20): 2721 - 2729.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
M. Decramer
Treatment of chronic respiratory failure: lung volume reduction surgery versus rehabilitation
Eur. Respir. J., November 16, 2003; 22(47_suppl): 47s - 56s.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
D. D. Sin, F. A. McAlister, S. F. P. Man, and N. R. Anthonisen
Contemporary Management of Chronic Obstructive Pulmonary Disease: Scientific Review
JAMA, November 5, 2003; 290(17): 2301 - 2312.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
The pharmacoepidemiology of COPD: Recent advances and methodological discussion
Eur. Respir. J., September 1, 2003; 22(43_suppl): 1s - 44s.
[Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
J. A Dougherty, B. L Didur, and L. S Aboussouan
Long-Acting Inhaled {beta}2-Agonists for Stable COPD
Ann. Pharmacother., September 1, 2003; 37(9): 1247 - 1255.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. Friedman
Formoterol and ipratropium in COPD
Am. J. Respir. Crit. Care Med., June 1, 2003; 167(11): 1579 - 1579.
[Full Text]

Home page
 Eur Respir JHome page
M. Wadbo, C-G. Lofdahl, K. Larsson, B.E. Skoogh, G. Tornling, E. Arwestrom, T. Bengtsson, and K. Strom
Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study
Eur. Respir. J., November 1, 2002; 20(5): 1138 - 1146.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
P.M.A. Calverley
Medical therapy for COPD: lessons from the real world
Eur. Respir. J., October 1, 2002; 20(4): 797 - 798.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
R. Aalbers, J. Ayres, V. Backer, M. Decramer, P.A. Lier, P. Magyar, J. Malolepszy, R. Ruffin, and G.W. Sybrecht
Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial
Eur. Respir. J., May 1, 2002; 19(5): 936 - 943.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
A. Rossi, P. Kristufek, B. E. Levine, M. H. Thomson, D. Till, J. Kottakis, and G. Della Cioppa
Comparison of the Efficacy, Tolerability, and Safety of Formoterol Dry Powder and Oral, Slow-Release Theophylline in the Treatment of COPD*
Chest, April 1, 2002; 121(4): 1058 - 1069.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. J. TOBIN
Chronic Obstructive Pulmonary Disease, Pollution, Pulmonary Vascular Disease, Transplantation, Pleural Disease, and Lung Cancer in AJRCCM 2001
Am. J. Respir. Crit. Care Med., March 1, 2002; 165(5): 642 - 662.
[Full Text] [PDF]

Home page
 DTBHome page
Managing stable chronic obstructive pulmonary disease
DTB, November 1, 2001; 39(11): 81 - 85.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2001 American Thoracic Society 		  ATS PAR News